Kenichi Mori

Kenichi Mori

Astellas Pharma Inc - Tokyo / Japan
Engineering & Technology / Computer Science
AD Scientific Index ID: 4405704
アステラス製薬株式会社
person_outline Kenichi Mori's MOST POPULAR ARTICLES
1-) Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemiaM Mori, N Kaneko, Y Ueno, M Yamada, R Tanaka, R Saito, I Shimada, ...Investigational new drugs 35 (5), 556-565, 20171592017
2-) Binding and aggregation mechanism of amyloid β-peptides onto the GM1 ganglioside-containing lipid membraneT Hoshino, MI Mahmood, K Mori, K MatsuzakiThe journal of physical chemistry B 117 (27), 8085-8094, 2013762013
3-) Formation of GM1 ganglioside clusters on the lipid membrane containing sphingomyeline and cholesterolK Mori, MI Mahmood, S Neya, K Matsuzaki, T HoshinoThe journal of physical chemistry B 116 (17), 5111-5121, 2012702012
4-) Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthaseK Ohno, K Mori, M Orita, M TakeuchiCurrent medicinal chemistry 18 (2), 220-233, 2011742011
5-) Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutationsTC Tarver, JE Hill, L Rahmat, AE Perl, E Bahceci, K Mori, CC SmithBlood advances 4 (3), 514-524, 2020722020